A Phase 3, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 (PE34) Process Administered Concomitantly with M-M-R II

Project: Research project

Project Details

StatusFinished
Effective start/end date8/21/17 → 8/20/19

Funding

  • Merck Sharp and Cohme Corporation: $6,100.00